Cas 876301-07-4,Benzenemethanamine, 2-[[3-(2-fluorophenyl)-1,2,4-triazolo[4,3-a]pyridin-6-yl]thio]-, monohydrochloride

876301-07-4

Post Buying Request

Basic information

Product Name: Benzenemethanamine, 2-[[3-(2-fluorophenyl)-1,2,4-triazolo[4,3-a]pyridin-6-yl]thio]-, monohydrochloride
Synonyms:
CAS NO:876301-07-4
Molecular Formula: C19H15FN4S.ClH
Molecular Weight: 386.88
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: Benzenemethanamine, 2-[[3-(2-fluorophenyl)-1,2,4-triazolo[4,3-a]pyridin-6-yl]thio]-, monohydrochloride(CAS DataBase Reference)
NIST Chemistry Reference: Benzenemethanamine, 2-[[3-(2-fluorophenyl)-1,2,4-triazolo[4,3-a]pyridin-6-yl]thio]-, monohydrochloride(876301-07-4)
EPA Substance Registry System: Benzenemethanamine, 2-[[3-(2-fluorophenyl)-1,2,4-triazolo[4,3-a]pyridin-6-yl]thio]-, monohydrochloride(876301-07-4)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 876301-07-4(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

876301-07-4 Suppliers

Recommended suppliers

876301-07-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 876301-07-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,6,3,0 and 1 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 876301-07:
(8*8)+(7*7)+(6*6)+(5*3)+(4*0)+(3*1)+(2*0)+(1*7)=174
174 % 10 = 4
So 876301-07-4 is a valid CAS Registry Number.

876301-07-4Upstream product

876301-07-4Downstream Products

876301-07-4Relevant academic research and scientific papers

Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors

-

Page/Page column 43, (2008/06/13)

A compound of formula (I), or a pharmaceutically acceptable salt and/or solvate (including hydrate) thereof; and the use of a compound of formula (I) in the treatment of a TNF-mediated disease, disorder, or condition, or a p38-mediated disease, disorder, or condition, in particular the allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 876301-07-4